Eli Lilly will collaborate on five drug candidates based on the Oxford and Karolinska Institute spinout's exosome delivery technology.
Evox Therapeutics, a UK-based exosome drug delivery technology spinout of University of Oxford and Karolinska Institute, has secured $10m of convertible funding from pharmaceutical firm Eli Lilly as part of a licensing and collaboration agreement.
Under the agreement, Eli Lilly will also supply $20m in an upfront payment as well as an undisclosed amount of research funding over the next three years.
Evox is also eligible for potential milestone payments up to a maximum of around $1.2bn and…
